(NASDAQ:ANGN) ANGION BIOMEDICA CORP, rallied at the end of the day today for a 18% gain in news of the annual shareholders meeting and recent H.C. Wainwright “Buy” rating of up to $32.00

HC Wainwright has removed Angion Biomedica Corp’s (NASDAQ:ANGN) former lead candidate, ANG-3777, in acute kidney injury (AKI), from its valuation assessment. The analyst has reduced the price target from $50 to $32, with a Buy rating.

In the Q4 earnings release, the Company decided to discontinue the development of ANG-3777 after disappointing data.

The analyst believes that the Company is better positioned than the market appears to think, particularly in light of the Company’s currently negative enterprise value of $(32.56) million, as per Benzinga Pro.

It possesses an extensive pipeline of assets beyond ANG-3777, which the market does not appear to be taking into consideration, analysts note.

Editor has purchased shares in this company.


Signup today for free and be the first to get notified of breaking news.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.


Sign up for Breaking Alerts, our newsletter putting timely and updated stock and crypto markets news into your hands.

Add New Playlist